Purpose

The purpose of this study is to learn more about infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some people know this virus by the name "coronavirus." It can cause the disease called COVID-19. The information gained from the study will be used to help develop better tests for SARS-CoV-2 infection and COVID-19 disease and may help in developing future vaccines and treatments by allowing researchers to determine the difference between the body's immune response to natural SARS-CoV-2 infection and immunization with a SARS-CoV-2 vaccine.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Age 18 or older. - Reports having had a positive test for SARS-CoV-2. - Reports resolution of COVID-19 within 1-8 weeks of enrollment OR, if asymptomatic infection, reports positive SARS-CoV-2 test within 2-10 weeks of enrollment. Not excluded: individuals with symptoms consistent with residual sequelae of resolved COVID-19, in the clinical judgement of the investigator. - Access to a participating HVTN or HPTN CRS and willingness to be followed for the planned duration of the study. - Ability and willingness to provide informed consent. - Assessment of understanding: volunteer demonstrates understanding of this study. - Volunteers who were assigned female sex at birth: negative urine or serum beta human chorionic gonadotropin (β-HCG) pregnancy test within 4 days of enrollment visit (ie, prior to enrollment blood draw or nasal collections). Persons who are NOT of reproductive potential due to having undergone hysterectomy or bilateral oophorectomy (verified by medical records) or having reached menopause (no menses for ≥ 1 year ), are not required to undergo pregnancy testing.

Exclusion Criteria

  • Reports current COVID-19. - Pregnant. - Receipt of SARS-CoV-2 specific antibodies (eg, convalescent plasma or sera, monoclonal antibodies, hyperimmune globulin). Not excluded: antibody therapy without SARS-CoV-2 specificity (eg, IL-6 pathway inhibitors for COVID-19). - SARS-CoV-2 vaccine(s) received in a prior vaccine trial. - Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence or a volunteer's ability to give informed consent.

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Other

Arm Groups

ArmDescriptionAssigned Intervention
Group 1 Persons not hospitalized for COVID-19, without clinical spectrum or outcomes specified in group 3 1A: Persons with asymptomatic infection, ages 18 through 55, inclusive 1B: Persons with asymptomatic infection, age > 55 1C: Persons with symptomatic infection (ie, COVID-19) ages 18 through 55 1D: Persons with symptomatic infection (ie, COVID-19), age > 55
  • Other: Sample collection
    Optional nasal specimen(s) Blood collection
Group 2 Persons previously hospitalized for COVID-19, without clinical spectrum or outcomes specified in group 3 2A: Persons 18 through 55 years of age 2B: Persons > 55 years of age
  • Other: Sample collection
    Optional nasal specimen(s) Blood collection
Group 3 Persons with specific clinical spectrums or outcomes, regardless of hospitalization history (eg, persons recovered after intubation, with prolonged viral shedding, with myocarditis/pericarditis, with rapid recovery from COVID-19, with a second positive SARS-CoV-2 RT-PCR test result after a negative result)
  • Other: Sample collection
    Optional nasal specimen(s) Blood collection

Recruiting Locations

Alabama Vaccine CRS
Birmingham, Alabama 35294
Contact:
CRS Leader
205-934-7349
msaag@uab.edu

UCLA CARE Center CRS
Los Angeles, California 90035
Contact:
CRS Leader
310-825-3782
rlandovitz@mednet.ucla.edu

Bridge HIV CRS
San Francisco, California 94143
Contact:
CRS Leader
415-437-7479
susan.buchbinder@sfdph.org

George Washington University CRS
Washington, District of Columbia 20037-1894
Contact:
CRS Leader
202-994-3024
manyadm@gwu.edu

The Ponce de Leon Center CRS
Atlanta, Georgia 30308-2012
Contact:
CRS Leader
404-727-1557
cdelrio@emory.edu

The Hope Clinic of the Emory Vaccine Center CRS
Decatur, Georgia 30030
Contact:
CRS Leader
404-712-1434
sedupug@emory.edu

Adolescent & Young Adult Research at The CORE Center (AYAR at CORE)
Chicago, Illinois 60612
Contact:
CRS Leader
312-864-4590
toyedele@cookcountyhhs.org

New Orleans Adolescent Trials Unit CRS
New Orleans, Louisiana 70112
Contact:
CRS Leader
504-988-3865
sabdali@tulane.edu

Johns Hopkins University CRS
Baltimore, Maryland 21205
Contact:
CRS Leader
443-287-0517
kdooley1@jhmi.edu

Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
Boston, Massachusetts 02115-6110
Contact:
CRS Leader
617-732-6801
lbaden@partners.org

Fenway Health Clinical Research Site CRS
Boston, Massachusetts 02215-4302
Contact:
CRS Leader
617-927-6087
kmayer@fenwayhealth.org

New Jersey Medical School Clinical Research Center CRS
Newark, New Jersey 07103
Contact:
CRS Leader
973-972-1057
swaminsh@njms.rutgers.edu

Bronx Prevention Research Center CRS
Bronx, New York 10451
Contact:
CRS Leader
212-342-0537
jj2158@cumc.columbia.edu

Harlem Prevention Center CRS
New York, New York 10027
Contact:
CRS Leader
212-939-2848
sbm20@cumc.columbia.edu

Columbia P&S CRS
New York, New York 10032-3732
Contact:
CRS Leader
212-305-7185
mes52@cumc.columbia.edu

New York Blood Center CRS
New York, New York 10065
Contact:
CRS Leader
212-570-3081
htieu@nybc.org

University of Rochester Vaccines to Prevent HIV Infection CRS
Rochester, New York 14642
Contact:
CRS Leader
585-275-5871
michael_keefer@urmc.rochester.edu

Chapel Hill CRS
Chapel Hill, North Carolina 27599
Contact:
CRS Leader
919-843-2723
wohl@med.unc.edu

Penn Prevention CRS
Philadelphia, Pennsylvania 19104
Contact:
CRS Leader
215-746-7346
franki@pennmedicine.upenn.edu

Vanderbilt Vaccine CRS
Nashville, Tennessee 37232-2582
Contact:
CRS Leader
615-322-8688
spyros.a.kalams@vanderbilt.edu

Seattle Vaccine and Prevention CRS
Seattle, Washington 98109-1024
Contact:
CRS Leader
206-667-6704
jmcelrat@fhcrc.org

More Details

NCT ID
NCT04403880
Status
Recruiting
Sponsor
HIV Vaccine Trials Network

Detailed Description

This study aims to characterize the SARS-CoV-2-specific immunity in convalescent individuals. The observational cohort study will include 3 groups, as described in the table below. Participants will complete a minimum of one visit (1-8 weeks post resolution of COVID-19 OR 2-10 weeks post most recent positive SARS-CoV-2 test, if asymptomatic) and optional visits approximately 2 months, 4 months, and 1 year later. Participants diagnosed with SARS-CoV-2 infection at an optional follow-up visit may be contacted more frequently. Additional follow up visit(s) may be added over time in response to evolving information regarding SARS-CoV-2 infection and COVID-19. Study visits may include physical examinations, medical history, questionnaires, pregnancy tests (for participants assigned female at birth), blood draws, optional nasal samples, and optional HIV testing.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.